Chronic Kidney Disease

New strategies and therapies are being developed to try and decrease the risk of bone disease and cardiovascular complications among people with severe kidney disease.

A machine learning model using routine clinical data more accurately predicted 5-year heart failure risk in patients with CKD than traditional tools.

A program in Detroit identified hundreds of patients with chronic kidney disease.

GLP-1s and SGLT2s were associated with improved kidney outcomes and no increased safety risks in patients with T1D and CKD.

Patients with both a low estimated glomerular filtration rate and a high protein-to-creatinine ratio were at particularly high risk of cognitive impairment, a new study has found.

Machine learning–based risk prediction models, particularly gradient boosting, can accurately identify early clinical indicators of CKD.

Many older HFpEF patients appear to have CKD from aging and obesity; visceral adiposity drives kidney risk more than intrinsic damage or low eGFR.

A systematic review reveals that cardiovascular risks emerge early in chronic kidney disease, highlighting the need for tailored management strategies.

Dyslipidemia significantly impacts cardiovascular risk in chronic kidney disease, necessitating tailored lipid management strategies for optimal patient outcomes.

Research reveals a potential link between preeclampsia and increased risks of chronic kidney disease, urging careful monitoring post pregnancy.

Modest weekend sleep recovery may reduce chronic kidney disease risk, especially for those with short weekday sleep duration.

Roy Mathew, MD, discusses integrating nephrology and cardiology to bridge the gap in patient adherence and care delivery.

Chronic kidney disease complicates cancer treatment, leading to reduced chemotherapy use. Personalized approaches are essential for optimal patient outcomes.

Experts advocate for a shift in CKD care towards prevention and maintaining kidney health, emphasizing lifestyle changes and early interventions.

Explore safe IBD treatment options for patients with chronic kidney disease, focusing on tailored approaches to optimize kidney health and medication efficacy.

This year’s most-read articles on CKD highlighted research and insights on drug approvals, guidelines, and value-based care.

Experts met in Park City, Utah, on October 7, 2025, to discuss how new technologies can help address chronic kidney disease.

Sibeprenlimab gains accelerated approval from the FDA for IgA nephropathy, showing significant proteinuria reduction and offering convenient self-injection treatment.

Chronic kidney disease now affects more than 788 million adults globally, with rising prevalence, increasing mortality, and substantial contributions to cardiovascular deaths

Improving outcomes in chronic kidney disease relies on improving patient engagement.

Finerenone significantly reduced UACR in type 1 diabetes with chronic kidney disease, offering new hope for treatment.

Researchers have developed a machine learning model that reliably predicts pulmonary hypertension (PH) risk in patients with chronic kidney disease (CKD).

Though patients with type 2 diabetes or chronic kidney disease (CKD) face a greater risk of heart failure (HF) following acute myocardial infarction (AMI), patients without those comorbidities also benefit from empagliflozin.

Overlapping metabolic mechanisms drive both chronic kidney disease (CKD) and valvular heart disease (VHD), a new review outlined.